Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):1001-1004. doi: 10.1051/medsci/2019198. Epub 2020 Jan 6.

[CD38 antibodies in multiple myeloma].

[Article in French; Abstract available in French from the publisher]

Author information

CHU Montpellier, Département d'hématologie biologique, Montpellier, France - IGH, CNRS, Univ Montpellier, France - Univ Montpellier, UFR de Médecine, Montpellier, France.


in English, French

The high CD38 expression by plasma cells together with the biological functions of CD38 resulted in the development of CD38 antibodies for the treatment of multiple myeloma (MM) patients. The cytolytic activity of CD38 antibodies is mediated by complement-dependent cytoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), direct cell death effects and immunomodulatory effects. CD38 antibodies have demonstrated their clinical benefit as single agent or in combination for the treatment of multiple myeloma patients and will contribute to further improvement in the outcome of MM patients.


Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center